The biology of interleukin-27 reveals unique pro- and anti-inflammatory functions in immunity

Cytokine and Growth Factor Reviews

Volumn 26, Issue 5, 2015, Pages 579-586

  Aparicio Siegmund, Samadhi ^a   Garbers, Christoph ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

EBI3; Gp130; Interleukin 27; P28; WSX 1

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 27; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; EBI3 PROTEIN, HUMAN; GLYCOPROTEIN GP 130; IL27 PROTEIN, HUMAN; IL27RA PROTEIN, HUMAN; IL6ST PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; INTERLEUKIN RECEPTOR; TUMOR PROTEIN;

CYTOKINE PRODUCTION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENETIC ASSOCIATION; HUMAN; INFECTION; INFLAMMATION; LYMPHOCYTE DIFFERENTIATION; NEOPLASM; NONHUMAN; PATHOGENESIS; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RHEUMATOID ARTHRITIS; SHORT SURVEY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH17 CELL; ANIMAL; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; IMMUNOLOGY; PATHOLOGY;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINE RECEPTOR GP130; HUMANS; INFECTION; INFLAMMATION; INTERLEUKINS; NEOPLASM PROTEINS; NEOPLASMS; RECEPTORS, INTERLEUKIN; SIGNAL TRANSDUCTION;

EID: 84941941096     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2015.07.008     Document Type: Short Survey

References (97)

1. Pflanz S., Timans J.C., Cheung J., et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002, 16:779-790.
2. Bazan J.F. Haemopoietic receptors and helical cytokines. Immunol. Today 1990, 11:350-354.
3. Villarino A., Hibbert L., Lieberman L., et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 2003, 19:645-655.
4. Villarino A.V., Stumhofer J.S., Saris C.J., Kastelein R.A., de Sauvage F.J., Hunter C.A. IL-27 limits IL-2 production during Th1 differentiation. J. Immunol. 2006, 176:237-247.
5. Diveu C., McGeachy M.J., Boniface K., et al. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J. Immunol. 2009, 182:5748-5756.
6. Hibbert L., Pflanz S., De Waal Malefyt R., Kastelein R.A. IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells. J. Interferon Cytokine Res. 2003, 23:513-522.
7. Stumhofer J.S., Laurence A., Wilson E.H., et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 2006, 7:937-945.
8. Crabé S., Guay-Giroux A., Tormo A.J., et al. The IL-27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulating NK and T cell activities requiring IL-6R for signaling. J. Immunol. 2009, 183:7692-7702.
9. Collison L.W., Vignali D.A. Interleukin-35: odd one out or part of the family?. Immunol. Rev. 2008, 226:248-262.
10. Garbers C., Spudy B., Aparicio-Siegmund S., et al. An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer. J. Biol. Chem. 2013, 288:4346-4354.
11. Matta B.M., Raimondi G., Rosborough B.R., Sumpter T.L., Thomson A.W. IL-27 production and STAT3-dependent upregulation of B7-H1 mediate immune regulatory functions of liver plasmacytoid dendritic cells. J. Immunol. 2012, 188:5227-5237.
12. Bosmann M., Russkamp N.F., Strobl B., et al. Interruption of macrophage-derived IL-27(p28) production by IL-10 during sepsis requires STAT3 but not SOCS3. J. Immunol. 2014, 193:5668-5677.
13. Charlot-Rabiega P., Bardel E., Dietrich C., Kastelein R., Devergne O. Signaling events involved in interleukin 27 (IL-27)-induced proliferation of human naive CD4+ T cells and B cells. J. Biol. Chem. 2011, 286:27350-27362.
14. Villarino A.V., Larkin J., Saris C.J., et al. Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. J. Immunol. 2005, 174:7684-7691.
15. Aparicio-Siegmund S., Moll J.M., Lokau J., et al. Recombinant p35 from bacteria can form interleukin (IL-)12, but not IL-35. PLoS ONE 2014, 9:e107990.
16. Collison L.W., Workman C.J., Kuo T.T., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-569.
17. Jones L., Chaturvedi V., Uyttenhove C., Van Snick J., Vignali D.A. Distinct subunit pairing criteria within the heterodimeric IL-12 cytokine family. Mol. Immunol. 2012, 51:234-244.
18. Garbers C., Hermanns H., Schaper F., et al. Plasticity and cross-talk of Interleukin 6-type cytokines. Cytokine Growth Factor Rev. 2012, 23:85-182.
19. Aparicio-Siegmund S., Sommer J., Monhasery N., et al. Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation. Oncotarget 2014, 5:2131-2148.
20. Guschin D., Rogers N., Briscoe J., et al. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. EMBO J. 1995, 14:1421-1429.
21. Heinrich P., Behrmann I., Haan S., Hermanns H., Müller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
22. Lucas S., Ghilardi N., Li J., de Sauvage F.J. IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:15047-15052.
23. Diegelmann J., Olszak T., Göke B., Blumberg S., Brand R.S. A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and anti-inflammatory proteins. J. Biol. Chem. 2012.
24. Pflanz S., Hibbert L., Mattson J., et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol. 2004, 172:2225-2231.
25. Owaki T., Asakawa M., Fukai F., Mizuguchi J., Yoshimoto T. IL-27 induces Th1 differentiation via p38 MAPK/T-bet- and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. J. Immunol. 2006, 177:7579-7587.
26. Kershaw N.J., Murphy J.M., Liau N.P., et al. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat. Struct. Mol. Biol. 2013, 20:469-476.
27. Babon J.J., Varghese L.N., Nicola N.A. Inhibition of IL-6 family cytokines by SOCS3. Semin. Immunol. 2014, 26:13-19.
28. Yasukawa H., Ohishi M., Mori H., et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 2003, 4:551-556.
29. Nicholson S.E., De Souza D., Fabri L.J., et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:6493-6498.
30. Hirahara K., Onodera A., Villarino A.V., et al. Asymmetric action of STAT transcription factors drives transcriptional outputs and cytokine specificity. Immunity 2015, 42:877-889.
31. Qiao Y., Giannopoulou E.G., Chan C.H., et al. Synergistic activation of inflammatory cytokine genes by interferon-gamma-induced chromatin remodeling and toll-like receptor signaling. Immunity 2013, 39:454-469.
32. Takeda A., Shinjiro H., Atsushi Y., et al. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-Bet through activation of STAT1 during initial Th1 commitment. J. Immunol. 2003, 170:4886-4890.
33. Li Q., Zhang L., Yang M., Xia R., Xia L., Liu F. Increased interleukin-27 promotes Th1 differentiation in patients with chronic immune thrombocytopenia. Scand. J. Immunol. 2014, 80:276-282.
34. Kamiya S., Okumura M., Chiba Y., et al. IL-27 suppresses RANKL expression in CD4+ T cells in part through STAT3. Immunol. Lett. 2011, 138:47-53.
35. Adamopoulos I.E., Pflanz S. The emerging role of interleukin 27 in inflammatory arthritis and bone destruction. Cytokine Growth Factor Rev. 2013, 24:115-121.
36. Young A., Linehan E., Hams E., et al. Cutting edge: suppression of GM-CSF expression in murine and human T cells by IL-27. J. Immunol. 2012, 189:2079-2083.
37. Aggarwal S., Ghilardi N., Xie M.-H.H., de Sauvage F.J., Gurney A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 2003, 278:1910-1914.
38. Mangan P.R., Harrington L.E., O'Quinn D.B., et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441:231-234.
39. Bettelli E., Carrier Y., Gao W., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
40. Jones G.W., McLoughlin R.M., Hammond V.J., et al. Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. J. Immunol. 2010, 184:2130-2139.
41. Kimura A., Naka T., Kishimoto T. IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:12099-12104.
42. Diveu C., McGeachy M.J., Boniface K., et al. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J. Immunol. (Baltimore Md.: 1950) 2009, 182:5748-5756.
43. Hirahara K., Ghoreschi K., Yang X.-P.P., et al. Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity 2012, 36:1017-1030.
44. El-behi M., Ciric B., Yu S., Zhang G.-X.X., Fitzgerald D.C., Rostami A. Differential effect of IL-27 on developing versus committed Th17 cells. J. Immunol. 2009, 183:4957-4967.
45. Neufert C., Becker C., Wirtz S., et al. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. Eur. J. Immunol. 2007, 37:1809-1816.
46. Fitzgerald D.C., Zhang G.X., El-Behi M. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol. 2007, 8(12):1372-1379.
47. Stumhofer J.S., Silver J.S., Laurence A., et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 2007, 8:1363-1371.
48. Banchereau J., Pascual V., O'Garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat. Immunol. 2012, 13:925-931.
49. Pot C., Jin H., Awasthi A., et al. Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J. Immunol. 2009, 183:797-801.
50. Heinemann C., Heink S., Petermann F., et al. IL-27 and IL-12 oppose pro-inflammatory IL-23 in CD4+ T cells by inducing Blimp1. Nat. Commun. 2014, 5:3770.
51. Yoshida H., Hamano S., Senaldi G., et al. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 2001, 15:569-578.
52. Artis D., Johnson L.M., Joyce K., et al. Cutting edge: early IL-4 production governs the requirement for IL-27-WSX-1 signaling in the development of protective Th1 cytokine responses following Leishmania major infection. J. Immunol. 2004, 172:4672-4675.
53. Rosas L.E., Satoskar A.A., Roth K.M., et al. Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to leishmania donovani infection but develop severe liver immunopathology. Am. J. Pathol. 2006, 168:158-169.
54. Hamano S., Himeno K., Miyazaki Y., Ishii K., Yamanaka A. WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity 2003, 19:657-667.
55. Bancroft A., Humphreys N., Worthington J., Yoshida H., Grencis R. WSX-1: a key role in induction of chronic intestinal nematode infection. J. Immunol. 2004, 172:7635-7641.
56. Artis D., Villarino A., Silverman M., et al. The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J. Immunol. 2004, 173:5626-5634.
57. Batten M., Li J., Yi S., et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol. 2006, 7:929-936.
58. Amadi-Obi A., Yu C.-R.R., Liu X., et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat. Med. 2007, 13:711-718.
59. Schmidt C., Giese T., Ludwig B., et al. Expression of interleukin 12 related cytokine transcripts in inflammatory bowel disease: elevated interleukin 23p19 and interleukin 27p28 in Crohn's disease but not in ulcerative colitis. Inflamm. Bowel Dis. 2005, 11:16-23.
60. Grivennikov S., Karin E., Terzic J., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
61. Bollrath J., Phesse T.J., von Burstin V.A., et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102.
62. Bromberg J. Stat proteins and oncogenesis. J. Clin. Invest. 2002, 109:1139-1142.
63. Bromberg J., Wrzeszczynska M., Devgan G., et al. Stat3 as an oncogene. Cell 1999, 98:295-303.
64. Pilati C., Amessou M., Bihl M., et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J. Exp. Med. 2011, 208:1359-1366.
65. Seita J., Asakawa M., Ooehara J., et al. Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood 2008, 111:1903-1912.
66. Lambert Q.T., Pradhan A., Roll J.D., Reuther G.W. Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity. Biochem. J. 2011, 438:155-164.
67. Hisada M., Kamiya S., Fujita K., et al. Potent antitumor activity of interleukin-27. Cancer Res. 2004, 64:1152-1156.
68. Salcedo R., Hixon J.A., Stauffer J.K., et al. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J. Immunol. 2009, 182:4328-4338.
69. Di Carlo E., Sorrentino C., Zorzoli A., et al. The antitumor potential of Interleukin-27 in prostate cancer. Oncotarget 2014, 5:10332-10341.
70. Kopf M., Baumann H., Freer G., et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994, 368:339-342.
71. McFarland-Mancini M., Funk H., Paluch A., et al. Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. J. Immunol. 2010, 184:7219-7228.
72. Schuster B., Kovaleva M., Sun Y., et al. Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin-6 receptor can serve as an alpha-receptor for CTNF. J. Biol. Chem. 2003, 278:9528-9535.
73. Tormo A., Meliani Y., Beaupré L., et al. The composite cytokine p28/cytokine-like factor 1 sustains B cell proliferation and promotes plasma cell differentiation. J. Immunol. 2013, 191:1657-1665.
74. Sommer J., Engelowski E., Baran P., Garbers C., Floss D.M., Scheller J. Interleukin-6, but not the interleukin-6 receptor plays a role in recovery from dextran sodium sulfate-induced colitis. Int. J. Mol. Med. 2014, 34:651-660.
75. Nieuwenhuis E.E., Neurath M.F., Corazza N., et al. Disruption of T helper 2-immune responses in Epstein-Barr virus-induced gene 3-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:16951-16956.
76. Dokmeci E., Xu L., Robinson E., Golubets K., Bottomly K., Herrick C.A. EBI3 deficiency leads to diminished T helper type 1 and increased T helper type 2 mediated airway inflammation. Immunology 2011, 132:559-566.
77. Zahn S., Wirtz S., Birkenbach M., Blumberg R.S., Neurath M.F., von Stebut E. Impaired Th1 responses in mice deficient in Epstein-Barr virus-induced gene 3 and challenged with physiological doses of Leishmania major. Eur. J. Immunol. 2005, 35:1106-1112.
78. Stumhofer J.S., Tait E.D., Quinn W.J., et al. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat. Immunol. 2010, 11:1119-1126.
79. Zhang S., Liang R., Luo W., et al. High susceptibility to liver injury in IL-27 p28 conditional knockout mice involves intrinsic interferon-γ dysregulation of CD4+ T cells. Hepatology 2013, 57:1620-1631.
80. Wang R.-X.X., Yu C.-R.R., Dambuza I.M., et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat. Med. 2014, 20:633-641.
81. Yoshida K., Taga T., Saito M. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:407-411.
82. Betz U.A., Bloch W., van den Broek M., et al. Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects. J. Exp. Med. 1998, 188:1955-1965.
83. Goldberg R., Zohar Y., Wildbaum G., Geron Y., Maor G., Karin N. Suppression of ongoing experimental autoimmune encephalomyelitis by neutralizing the function of the p28 subunit of IL-27. J. Immunol. 2004, 173:6465-6471.
84. Goldberg R., Wildbaum G., Zohar Y., Maor G., Karin N. Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27. J. Immunol. 2004, 173:1171-1178.
85. Cao Y., Doodes P.D., Glant T.T., Finnegan A. IL-27 induces a Th1 immune response and susceptibility to experimental arthritis. J. Immunol. 2008, 180:922-930.
86. Wong C.K., Chen D.P., Tam a.P., Li L.S., Yin E.K., Lam Y.B.C.W. Effects of inflammatory cytokine IL-27 on the activation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res. Ther. 2010, 12.
87. Shen H., Xia L., Xiao W., Lu J. Increased levels of interleukin-27 in patients with rheumatoid arthritis. Arthritis Rheum. 2011, 63:860-861.
88. Niedbala W., Cai B., Wei X., et al. Interleukin 27 attenuates collagen-induced arthritis. Ann. Rheum. Dis. 2008, 67:1474-1479.
89. Tanida S., Yoshitomi H., Ishikawa M., Kasahara T. IL-27-producing CD14+ cells infiltrate inflamed joints of rheumatoid arthritis and regulate inflammation and chemotactic migration. Cytokine 2011, 55:237-244.
90. Baek S.H., Lee S.G., Park Y.E., Kim G.T., Kim C.D., Park S.Y. Increased synovial expression of IL-27 by IL-17 in rheumatoid arthritis. Imflamm. Res. 2012, 61:1339-1345.
91. Cox J.H., Kljavin N.M., Ramamoorthi N., Diehl L., Batten M., Ghilardi N. IL-27 promotes T cell-dependent colitis through multiple mechanisms. J. Exp. Med. 2011, 208:115-123.
92. Wirtz S., Tubbe I., Galle P.R., et al. Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27. J. Exp. Med. 2006, 203:1875-1881.
93. Jones S.A., Scheller J., Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 2011, 121:3375-3383.
94. Garbers C., Aparicio-Siegmund S., Rose-John S. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr. Opin. Immunol. 2015, 34:75-82.
95. Scheller J., Schuster B., Hölscher C., Yoshimoto T., Rose-John S. No inhibition of IL-27 signaling by soluble gp130. Biochem. Biophys. Res. Commun. 2005, 326:724-728.
96. Wolf J., Rose-John S., Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 2014, 70:11-20.
97. Dietrich C., Candon S., Ruemmele F.M., Devergne O. A soluble form of IL-27Rα is a natural IL-27 antagonist. J. Immunol. 2014, 192:5382-5389.